188 related articles for article (PubMed ID: 25884512)
21. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
Schrock AB; Li SD; Frampton GM; Suh J; Braun E; Mehra R; Buck SC; Bufill JA; Peled N; Karim NA; Hsieh KC; Doria M; Knost J; Chen R; Ou SI; Ross JS; Stephens PJ; Fishkin P; Miller VA; Ali SM; Halmos B; Liu JJ
J Thorac Oncol; 2017 Jun; 12(6):932-942. PubMed ID: 28315738
[TBL] [Abstract][Full Text] [Related]
22. Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling.
Ou SH; Chalmers ZR; Azada MC; Ross JS; Stephens PJ; Ali SM; Miller VA
Lung Cancer; 2015 Jun; 88(3):352-4. PubMed ID: 25851827
[TBL] [Abstract][Full Text] [Related]
23. An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers.
Dama E; Melocchi V; Dezi F; Pirroni S; Carletti RM; Brambilla D; Bertalot G; Casiraghi M; Maisonneuve P; Barberis M; Viale G; Vecchi M; Spaggiari L; Bianchi F; Di Fiore PP
Clin Cancer Res; 2017 Jan; 23(1):62-72. PubMed ID: 27358486
[TBL] [Abstract][Full Text] [Related]
24. Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC).
Kumarakulasinghe NB; van Zanwijk N; Soo RA
Respirology; 2015 Apr; 20(3):370-8. PubMed ID: 25689095
[TBL] [Abstract][Full Text] [Related]
25. Genomic and transcriptional alterations in lung adenocarcinoma in relation to smoking history.
Karlsson A; Ringnér M; Lauss M; Botling J; Micke P; Planck M; Staaf J
Clin Cancer Res; 2014 Sep; 20(18):4912-24. PubMed ID: 25037737
[TBL] [Abstract][Full Text] [Related]
26. Multiplex genomic test of mutation and fusion genes in small biopsy specimen of lung cancer.
Oshita F; Kasajima R; Miyagi Y
J Exp Ther Oncol; 2016 Jul; 11(3):189-194. PubMed ID: 28471124
[TBL] [Abstract][Full Text] [Related]
27. RET-rearranged lung adenocarcinomas with lymphangitic spread, psammoma bodies, and clinical responses to cabozantinib.
Mukhopadhyay S; Pennell NA; Ali SM; Ross JS; Ma PC; Velcheti V
J Thorac Oncol; 2014 Nov; 9(11):1714-9. PubMed ID: 25436805
[TBL] [Abstract][Full Text] [Related]
28. High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.
Wiesweg M; Eberhardt WEE; Reis H; Ting S; Savvidou N; Skiba C; Herold T; Christoph DC; Meiler J; Worm K; Kasper S; Theegarten D; Hense J; Hager T; Darwiche K; Oezkan F; Aigner C; Welter S; Kühl H; Stuschke M; Schmid KW; Schuler M
J Thorac Oncol; 2017 Jan; 12(1):54-64. PubMed ID: 27575422
[TBL] [Abstract][Full Text] [Related]
29. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
[TBL] [Abstract][Full Text] [Related]
30. Personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
[TBL] [Abstract][Full Text] [Related]
31. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
32. Genomic Testing in Lung Cancer: Past, Present, and Future.
Mascaux C; Tsao MS; Hirsch FR
J Natl Compr Canc Netw; 2018 Mar; 16(3):323-334. PubMed ID: 29523671
[TBL] [Abstract][Full Text] [Related]
33. Lung adenocarcinoma: lessons in translation from bench to bedside.
Sangodkar J; Katz S; Melville H; Narla G
Mt Sinai J Med; 2010; 77(6):597-605. PubMed ID: 21105123
[TBL] [Abstract][Full Text] [Related]
34. ALK positivity on pleuroscopic pleural biopsy in lung adenocarcinoma.
Vaidya PJ; Kate AH; Mehta D; Dhabar BN; Chhajed PN
J Cancer Res Ther; 2016; 12(2):1090-2. PubMed ID: 27461706
[TBL] [Abstract][Full Text] [Related]
35. Current Landscape of Targeted Therapy in Lung Cancer.
Mayekar MK; Bivona TG
Clin Pharmacol Ther; 2017 Nov; 102(5):757-764. PubMed ID: 28786099
[TBL] [Abstract][Full Text] [Related]
36. Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinoma-a single center retrospective study.
Velizheva NP; Rechsteiner MP; Valtcheva N; Freiberger SN; Wong CE; Vrugt B; Zhong Q; Wagner U; Moch H; Hillinger S; Schmitt-Opitz I; Soltermann A; Wild PJ; Tischler V
Pathol Res Pract; 2018 Apr; 214(4):572-578. PubMed ID: 29580750
[TBL] [Abstract][Full Text] [Related]
37. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.
Juchum M; Günther M; Laufer SA
Drug Resist Updat; 2015 May; 20():12-28. PubMed ID: 26021435
[TBL] [Abstract][Full Text] [Related]
38. Genomics-driven oncology: framework for an emerging paradigm.
Garraway LA
J Clin Oncol; 2013 May; 31(15):1806-14. PubMed ID: 23589557
[TBL] [Abstract][Full Text] [Related]
39. Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?
Ou SH
J Clin Pathol; 2013 Oct; 66(10):839-46. PubMed ID: 23661716
[TBL] [Abstract][Full Text] [Related]
40. Population-level effect of molecular testing and targeted therapy in patients with advanced pulmonary adenocarcinoma: a prospective cohort study.
Schwegler C; Kaufmann D; Pfeiffer D; Aebi S; Diebold J; Gautschi O
Virchows Arch; 2018 Apr; 472(4):581-588. PubMed ID: 29198034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
